Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study
Background: Advanced pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis with a 5-year survival rate of 3%. While treated as an even population, previous retrospective studies suggested significantly different survival rates for patients with lung-only metastases when compared with ot...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2025-06-01
|
| Col·lecció: | ESMO Gastrointestinal Oncology |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S2949819825000135 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
